As global markets show signs of resilience with U.S. indexes approaching record highs and broad-based gains, investors are navigating through geopolitical uncertainties and economic shifts. Amidst this backdrop, growth companies with high insider ownership can offer unique insights into potential investment opportunities, as insiders often have a vested interest in the long-term success of their firms.
Name | Insider Ownership | Earnings Growth |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
SKS Technologies Group (ASX:SKS) | 32.4% | 24.8% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.3% |
Laopu Gold (SEHK:6181) | 36.4% | 34% |
On Holding (NYSE:ONON) | 19.1% | 29.6% |
Pharma Mar (BME:PHM) | 11.8% | 56.9% |
Elliptic Laboratories (OB:ELABS) | 26.8% | 103.6% |
Credo Technology Group Holding (NasdaqGS:CRDO) | 13.7% | 95% |
Alkami Technology (NasdaqGS:ALKT) | 11% | 98.6% |
Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Selvas AI Inc. is a South Korean company specializing in artificial intelligence, with a market cap of ₩357.69 billion.
Operations: The company's revenue is derived from several segments: Medical Diagnosis Device (₩15.17 billion), Assistive Technology Equipment (₩13.34 billion), Artificial Intelligence-Based Technology (₩7.85 billion), and Artificial Intelligence Application Solution, including Electronic Dictionary (₩16.06 billion).
Insider Ownership: 13.1%
Revenue Growth Forecast: 20.2% p.a.
Selvas AI is poised for significant growth, with revenue projected to increase by 20.2% annually, outpacing the Korean market's 9.1% growth rate. Although there has been no substantial insider trading activity recently, the company is expected to achieve profitability within three years, which surpasses average market expectations. However, its forecasted Return on Equity of 6.8% in three years remains relatively low compared to benchmarks.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Chengdu Olymvax Biopharmaceuticals Inc. focuses on the research, development, production, and sale of human vaccines and has a market cap of CN¥4.43 billion.
Operations: The company's revenue primarily comes from its Medicine Manufacturing segment, totaling CN¥530.47 million.
Insider Ownership: 24.5%
Revenue Growth Forecast: 21.7% p.a.
Chengdu Olymvax Biopharmaceuticals is positioned for robust growth, with revenue expected to rise 21.7% annually, surpassing the Chinese market's growth rate. Despite no recent substantial insider trading activity, the company is forecasted to achieve profitability within three years, indicating strong potential. However, its projected Return on Equity at 10.5% in three years is relatively low. Recent earnings show sales of CNY 386.65 million but a decline in net income to CNY 4.03 million year-over-year.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Xiamen Wanli Stone Stock Co., Ltd specializes in the development, processing, and installation of stone products, construction stones, stone carving handicrafts, and mineral products across China, Japan, South Korea, the United States, and other international markets with a market cap of CN¥7.96 billion.
Operations: The company's revenue primarily comes from the Stone Processing and Manufacturing Industry, amounting to CN¥1.01 billion.
Insider Ownership: 18.9%
Revenue Growth Forecast: 19.2% p.a.
Xiamen Wanli Stone Stock Ltd is anticipated to achieve profitability within three years, with revenue growth outpacing the broader Chinese market at 19.2% annually. Despite no significant insider trading recently, earnings are projected to grow significantly at over 100% per year. However, recent results show modest sales growth to CNY 911.25 million and a decline in net income to CNY 2.44 million, reflecting challenges in current profitability and return on equity forecasted at a low 15.3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com